Back to Search Start Over

Implication of folate deficiency in CYP2U1 loss of function.

Authors :
Pujol C
Legrand A
Parodi L
Thomas P
Mochel F
Saracino D
Coarelli G
Croon M
Popovic M
Valet M
Villain N
Elshafie S
Issa M
Zuily S
Renaud M
Marelli-Tosi C
Legendre M
Trimouille A
Kemlin I
Mathieu S
Gleeson JG
Lamari F
Galatolo D
Alkouri R
Tse C
Rodriguez D
Ewenczyk C
Fellmann F
Kuntzer T
Blond E
El Hachimi KH
Darios F
Seyer A
Gazi AD
Giavalisco P
Perin S
Boucher JL
Le Corre L
Santorelli FM
Goizet C
Zaki MS
Picaud S
Mourier A
Steculorum SM
Mignot C
Durr A
Trifunovic A
Stevanin G
Source :
The Journal of experimental medicine [J Exp Med] 2021 Nov 01; Vol. 218 (11). Date of Electronic Publication: 2021 Sep 21.
Publication Year :
2021

Abstract

Hereditary spastic paraplegias are heterogeneous neurodegenerative disorders. Understanding of their pathogenic mechanisms remains sparse, and therapeutic options are lacking. We characterized a mouse model lacking the Cyp2u1 gene, loss of which is known to be involved in a complex form of these diseases in humans. We showed that this model partially recapitulated the clinical and biochemical phenotypes of patients. Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far. We also confirmed brain calcifications as a potential biomarker in patients. Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues.<br />Competing Interests: Disclosures: F. Darios reports "other" from Dynacure SAS outside the submitted work. D. Galatolo is supported by a grant from Treat SPG56. G. Stevanin reports grants from ASL-HSP association, the Tom-Wahlig-Stiftung Foundation, and the European Union 7th Framework Programme (Neuromics); non-financial support from Agence Nationale de la Recherche (framework programme Investissements d'Avenir) during the conduct of the study; and grants from Biogen outside the submitted work. N. Vilain reports grants from Fondation Bettencourt-Schueller, Fondation Servier, Union Nationale pour les Intérêts de la Médecine, and Fondation pour la Recherche sur l'Alzheimer; non-financial support from Movement Disorders Society, Merz-Pharma, and GE Healthcare SAS; and "other" from Biogen, Eisai, Eli-Lilly, Roche, Janssen - Johnson & Johnson, and Alector outside the submitted work. No other disclosures were reported.<br /> (© 2021 Pujol et al.)

Details

Language :
English
ISSN :
1540-9538
Volume :
218
Issue :
11
Database :
MEDLINE
Journal :
The Journal of experimental medicine
Publication Type :
Academic Journal
Accession number :
34546337
Full Text :
https://doi.org/10.1084/jem.20210846